Tesamorelin (20 mg Vial) – Dosage Protocol
Contents
- Quickstart Highlights
- Dosing & Reconstitution Guide
- Standard FDA-Approved Protocol (3.0 mL = ~6.67 mg/mL)
- Reconstitution Steps
- Supplies Needed
- Protocol Overview
- Dosing Protocol
- Storage Instructions
- Important Notes
- How This Works
- Potential Benefits & Side Effects
- Lifestyle Factors
- Injection Technique
- Recommended Source
- Important Note
- References
Quickstart Highlights
Tesamorelin is a synthetic peptide made up of 44 amino acids and acts as an analog of Growth Hormone-Releasing Hormone (GHRH). It works by stimulating the body’s natural production of growth hormone and increasing IGF-1 levels, which helps improve fat metabolism and overall metabolic function.
It is FDA-approved for reducing visceral fat in individuals with HIV-associated lipodystrophy and is also being studied for broader metabolic and aging-related benefits.
- Reconstitution: Add 3.0 mL bacteriostatic water to a 20 mg vial → resulting concentration ~6.67 mg/mL
- Standard Daily Dose: 2 mg (2000 mcg), once daily
- Measurement Guide: At this concentration, 1 unit (0.01 mL) ≈ 66.7 mcg on a U-100 insulin syringe
- Storage: Refrigerate at 2–8°C; after reconstitution, use within 7 days
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard FDA-Approved Protocol (3.0 mL = ~6.67 mg/mL)
| Week | Daily Dose (mg / mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 1 mg / 1000 mcg | 15 units (0.15 mL) |
| Weeks 2–12+ | 2 mg / 2000 mcg | 30 units (0.30 mL) |
Frequency: Once daily via subcutaneous injection, preferably in the evening to align with natural growth hormone release.
A one-week lower dose phase is recommended to improve tolerability before moving to the full dose.
Reconstitution Steps
- Using a sterile syringe, draw 3.0 mL bacteriostatic water.
- Slowly inject the liquid down the inside wall of the vial to minimize foaming.
- Gently swirl or roll the vial until the powder is fully dissolved. Avoid shaking, as peptides are delicate.
- Clearly label the vial and place it in refrigeration (2–8°C), away from direct light exposure.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Based on an 8–16 week daily protocol:
Tesamorelin Vials (20 mg each)
- 8 weeks: ~6 vials
- 12 weeks: ~9 vials
- 16 weeks: ~11 vials
Insulin Syringes (U-100)
- 7 per week
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles)
- 8 weeks: ~18 mL (2 bottles)
- 12 weeks: ~27 mL (3 bottles)
- 16 weeks: ~33 mL (4 bottles)
Alcohol Swabs
- 2 per day
- 8 weeks: 112 swabs
- 12 weeks: 168 swabs
- 16 weeks: 224 swabs
Protocol Overview
- Goal: Reduce visceral fat and improve metabolic health
- Schedule: Daily injections for 12–26 weeks (extendable up to 52 weeks with supervision)
- Dose: 2 mg daily after Week 1
- Reconstitution: 3.0 mL per vial
- Storage: Refrigerated before and after mixing
Dosing Protocol
- Week 1: 1 mg daily (tolerance phase)
- Weeks 2+: 2 mg daily (standard dose)
- Frequency: Once daily (subcutaneous)
- Timing: Preferably evening
- Cycle Length: 12–26 weeks
Storage Instructions
Proper storage is essential to maintain the quality and effectiveness of the peptide.
- Lyophilized (unmixed): Keep refrigerated at 2–8°C (35.6–46.4°F). Some newer formulations (such as Egrifta SV) may remain stable at room temperature (20–25°C / 68–77°F) before mixing.
- After reconstitution (with bacteriostatic water): Store in the refrigerator at 2–8°C and use within 7 days.
- After reconstitution (with sterile water): Use immediately and discard any remaining solution.
- Avoid freezing the mixed solution and do not subject it to repeated freeze–thaw cycles.
Important Notes
- Use a new sterile insulin syringe (27–30G) for each injection
- Dispose of all sharps safely after use
- Rotate injection sites to minimize irritation or tissue buildup
- Inject slowly and wait briefly before removing the needle
- Common temporary effects may include nausea, flushing, or mild headache
- Keeping a simple log of dose and injection site can help maintain consistency
How This Works
Tesamorelin mimics natural GHRH and binds to receptors in the pituitary gland, triggering the release of growth hormone. This leads to increased IGF-1 production, which promotes fat breakdown (lipolysis), muscle preservation, and metabolic improvements.
Clinical research has shown significant reductions in visceral fat and improvements in lipid profiles. It is also being explored for applications in liver fat reduction and cognitive support.
Potential Benefits & Considerations
Potential Benefits
- Reduction in visceral adipose tissue
- Improved metabolic and lipid profiles
- Support for fat loss and body composition
- Possible cognitive and anti-aging benefits
Common Side Effects
- Injection site irritation (redness, itching)
- Mild swelling or joint discomfort
- Temporary fluid retention
Contraindications
- Active malignancy
- Pregnancy
- Hypersensitivity to Tesamorelin
Lifestyle Factors
For optimal outcomes, consider combining with supportive habits:
- Maintain consistent sleep (7–9 hours per night)
- Engage in regular physical activity
- Practice stress management (meditation, breathing exercises)
- Ensure proper nutrition (protein, omega-3s, micronutrients)
- Limit alcohol and excessive stimulant intake
Injection Technique
- Wash hands and prepare a clean surface
- Clean vial stopper with alcohol swab
- Draw correct dosage into syringe and remove air bubbles
- Clean injection site and allow to dry
- Pinch skin and inject at a 90° angle
- Inject slowly and steadily
- Remove needle and apply gentle pressure if needed
- Dispose of syringe safely (do not reuse)
- Rotate injection sites regularly
Recommended Source
We recommend Fit Aminos for high-purity research peptide products.
Why Fit Aminos?
- High-purity, lab-tested peptide batches with quality verification.
- Consistent handling and preparation processes designed to support reliable research protocols.
- Transparent sourcing and dependable fulfillment for research-grade compounds.
Important Note
This content is intended for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment. TESAMORELIN (20mg) remains an investigational peptide with limited human clinical data. For research use only. Not for human consumption.
References
Tesamorelin – LiverTox: Clinical and Research Information on Drug-Induced Liver Injury — National Institutes of Health, NIDDK (2018)
Tesamorelin (Subcutaneous route) – Drug Information — Mayo Clinic / IBM Merative (2025)
Effects of tesamorelin (TH9507), a growth hormone–releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials
— J. Clin. Endocrinol. Metab. (2010)
Safety and metabolic effects of tesamorelin in patients with type 2 diabetes: A randomized, placebo-controlled trial — PLoS ONE (2017)
Journal of Higher Nervous Activity (Russia) — Early human study introducing Semax’s nootropic properties and mechanism of action